



(11) **EP 1 628 530 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
01.08.2012 Bulletin 2012/31

(45) Date of publication and mention
of the grant of the patent:
06.06.2012 Bulletin 2012/23

(21) Application number: **04752211.5**

(22) Date of filing: **14.05.2004**

(51) Int Cl.:
A61K 39/395 ^(2006.01) **A61K 38/00** ^(2006.01)
A61P 31/00 ^(2006.01) **A01N 37/18** ^(2006.01)

(86) International application number:
PCT/US2004/015135

(87) International publication number:
WO 2004/103294 (02.12.2004 Gazette 2004/49)

(54) **METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SEPSIS**
VERFAHREN UND ZUBEREITUNGEN ZUR VORBEUGUNG UND BEHANDLUNG VON SEPSIS
PROCEDES ET COMPOSITIONS POUR LA PREVENTION ET LE TRAITEMENT DE LA SEPSIE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PL PT RO SE SI SK TR**

(30) Priority: **15.05.2003 US 470681 P**

(43) Date of publication of application:
01.03.2006 Bulletin 2006/09

(60) Divisional application:
10179747.0 / 2 266 606

(73) Proprietors:
• **Genentech, Inc.**
South San Francisco CA 94080-4990 (US)
• **MEDINNOVA AS**
0027 Oslo (NO)

(72) Inventors:
• **FUNG, Sek Chung**
Houston, TX 77025 (US)
• **MOLLNES, Tom Eirik**
N-8013 Bodø (NO)

(74) Representative: **Evenson, Jane Harriet et al**
Mathys & Squire LLP
120 Holborn
London EC1N 2SQ (GB)

(56) References cited:
WO-A-01/15731 WO-A-03/015819
US-A1- 2002 034 509 US-A1- 2002 044 929
US-B1- 6 297 049

- **MOLLNES TOM EIRIK ET AL: "Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation" BLOOD, vol. 100, no. 5, 1 September 2002 (2002-09-01), pages 1869-1877, XP002440770 ISSN: 0006-4971**
- **LETURCQ DIDIER J ET AL: "Antibodies against CD14 protect primates from endotoxin-induced shock" JOURNAL OF CLINICAL INVESTIGATION, vol. 98, no. 7, 1996, pages 1533-1538, XP002440771 ISSN: 0021-9738**
- **HUBER-LANG MARKUS S ET AL: "Protection of innate immunity by C5aR antagonist in septic mice" FASEB JOURNAL, vol. 16, no. 12, October 2002 (2002-10), pages 1567-1574, XP002440772 ISSN: 0892-6638**
- **MOLLNES ET AL.: 'Inhibition of endotoxin-induced oxidative burst by the C3 binding peptide compstatin in a novel whole blood model of inflammation' IMMUNOPHARMACOLOGY vol. 49, no. 1-2, August 2000, page 62, XP002985846**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 628 530 B8